Physician profile
Huma Khan
NPI 1770142846
$1,103.98
in general payments reported to CMS, 2019-2025
14 companies · $883 in 2025
The $883 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.28 · 2022: $20.66 · 2024: $183 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $187.65 | 2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $169.29 | 2025 | |
| Aerin Medical INC. | $155.45 | 2025 | |
| Grifols USA, LLC | $124.99 | 2025 | Xembify |
| Genentech USA, INC. | $115.20 | 2024 | Xolair |
| Glaxosmithkline, LLC. | $102.44 | 2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $49.17 | 2024 | Krystexxa, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $45.94 | 2022-2025 | Cuvitru |
| Ars Pharmaceuticals Operations, INC. | $45.76 | 2025 | Neffy |
| Organon LLC | $36.55 | 2025 | |
| Optinose US, INC. | $20.69 | 2025 | |
| Kaleo, INC. | $18.40 | 2024 | Auvi-Q |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.28 | 2021 | |
| Heron Therapeutics, INC. | $15.17 | 2025 | Aponvie |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.